GlassScriptPhysician profile
Samuel W Cole
NPI 1023294527
$2,517.16
in general payments reported to CMS, 2019-2025
25 companies · $560 in 2025
The $560 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $117 · 2021: $505 · 2022: $343 · 2023: $362 · 2024: $356 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $725.97 | 2019-2025 | Liletta, Vraylar, Lo Loestrin Fe |
| Astellas Pharma US INC | $276.62 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $204.94 | 2021-2025 | Slynd, Solosec |
| Biogen, INC. | $199.73 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $176.35 | 2021 | |
| Hologic Sales and Service, LLC | $139.34 | 2022-2025 | Myosure Tissue Removal Device, Novasure, Omni Hysteroscope |
| Mayne Pharma Commercial LLC | $124.15 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.76 | 2019-2023 | |
| Organon LLC | $88.65 | 2021-2025 | Nexplanon, Jada System |
| Pfizer INC. | $87.30 | 2019-2025 | |
| Allergan, INC. | $48.79 | 2019-2020 | |
| Amgen INC. | $48.15 | 2024-2025 | Evenity, Prolia |
| Becton, Dickinson and Company | $43.84 | 2024 | Arista Ah Flexitip |
| Merck Sharp & Dohme LLC | $32.36 | 2019-2022 | |
| Minerva Surgical, INC | $27.87 | 2020-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.19 | 2023-2024 | Injectafer |
| Axonics, INC. | $24.25 | 2021 | |
| Roche Diagnostics Corporation | $18.62 | 2019 | |
| Sumitomo Pharma America, INC. | $17.96 | 2023 | Myfembree |
| Davol INC. | $17.95 | 2022 | |
| Millicent US INC | $16.13 | 2025 | Intrarosa, Femring |
| Amag Pharmaceuticals, INC. | $15.31 | 2019 | |
| Avion Pharmaceuticals | $15.00 | 2022 | |
| Medtronic Vascular, INC. | $14.73 | 2020 | |
| Avanos Medical | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.